{"id":"W2582709627","doi":"10.1016/s1474-4422(16)30399-4","title":"Safety and efficacy of ozanezumab in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled, phase 2 trial","year":2017,"lang":"en","type":"article","venue":"The Lancet Neurology","topic":"Amyotrophic Lateral Sclerosis Research","field":"Medicine","cited_by":85,"is_retracted":false,"has_abstract":false,"ca_institutions":"Montreal Neurological Institute and Hospital","funders":"Italfarmaco; Baxalta; European Commission; Cytokinetics; Biogen; GlaxoSmithKline","keywords":"Medicine; Placebo; Amyotrophic lateral sclerosis; Internal medicine; Clinical trial; Adverse effect; Clinical endpoint; Physical therapy; Disease; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001885259,0.002710646,0.004262001,0.0005384556,0.0005743026,0.00142522,0.0009449025,0.003113957,0.00573596],"category_scores_gemma":[0.002198582,0.0009173541,0.002397225,0.0004994332,0.001646793,0.001908048,0.0005256206,0.003097004,0.001270899],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009141637,"about_ca_system_score_gemma":0.0009685908,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009058258,"about_ca_topic_score_gemma":0.001312704,"domain_scores_codex":[0.9991813,0.0003751656,0.00007187078,0.0001721475,0.00006631385,0.0001331933],"domain_scores_gemma":[0.9991222,0.0002833953,0.0002230749,0.00006160674,0.00006900648,0.0002407706],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9911017,0.001019891,0.0002850494,0.0005806168,0.0005700848,0.00003004906,0.00003227587,0.00009026991,0.001502841,0.0000464652,0.0002988242,0.004441866],"study_design_scores_gemma":[0.9813052,0.01673725,0.0009360642,0.00002426189,0.000364016,0.00002031626,0.00001458008,0.0001140031,0.0001347861,0.00007921774,0.0002598728,0.00001042344],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9779969,0.01279759,0.0007673771,0.001220144,0.0010158,0.002748935,0.00121997,0.0001330209,0.0021003],"genre_scores_gemma":[0.9832343,0.005603389,0.001114649,0.001535228,0.0006738717,0.003561702,0.001430476,0.0000342162,0.002812224],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00573596,"threshold_uncertainty_score":0.0191887,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0582750514239321,"score_gpt":0.3281753930159591,"score_spread":0.269900341592027,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}